Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

2021132 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 22, Issue 5, pp. 678-689

Field-Weighted Citation Impact: 16.99